Nabriva Therapeutics AG (NBRV) Major Shareholder Sells $207,931.50 in Stock

Nabriva Therapeutics AG (NASDAQ:NBRV) major shareholder Hbm Healthcare Investments (Ca sold 19,803 shares of the firm’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $10.50, for a total transaction of $207,931.50. Following the transaction, the insider now directly owns 2,373,387 shares of the company’s stock, valued at $24,920,563.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Hbm Healthcare Investments (Ca also recently made the following trade(s):

  • On Monday, August 7th, Hbm Healthcare Investments (Ca sold 17,790 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.50, for a total transaction of $186,795.00.
  • On Friday, July 28th, Hbm Healthcare Investments (Ca sold 6,585 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.51, for a total transaction of $69,208.35.
  • On Monday, July 24th, Hbm Healthcare Investments (Ca sold 160 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.50, for a total transaction of $1,680.00.
  • On Thursday, July 20th, Hbm Healthcare Investments (Ca sold 44,231 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.50, for a total transaction of $464,425.50.
  • On Tuesday, July 18th, Hbm Healthcare Investments (Ca sold 69,854 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.51, for a total transaction of $734,165.54.
  • On Thursday, July 13th, Hbm Healthcare Investments (Ca sold 57,175 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.53, for a total transaction of $602,052.75.
  • On Friday, July 7th, Hbm Healthcare Investments (Ca sold 2,695 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.52, for a total transaction of $28,351.40.
  • On Friday, June 30th, Hbm Healthcare Investments (Ca sold 1,775 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.94, for a total transaction of $19,418.50.
  • On Monday, July 3rd, Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.94, for a total transaction of $143,609.38.
  • On Thursday, June 29th, Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.96, for a total transaction of $93,795.68.

Nabriva Therapeutics AG (NBRV) opened at 10.00 on Friday. Nabriva Therapeutics AG has a 52 week low of $3.52 and a 52 week high of $12.75. The firm has a 50 day moving average of $10.40 and a 200-day moving average of $10.35. The stock’s market capitalization is $268.38 million.

Nabriva Therapeutics AG (NASDAQ:NBRV) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($5.83) by $5.29. The business had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.34 million. On average, equities analysts predict that Nabriva Therapeutics AG will post ($2.43) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Nabriva Therapeutics AG (NBRV) Major Shareholder Sells $207,931.50 in Stock” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/08/12/nabriva-therapeutics-ag-nbrv-major-shareholder-sells-207931-50-in-stock.html.

Large investors have recently added to or reduced their stakes in the company. Almanack Investment Partners LLC. acquired a new stake in Nabriva Therapeutics AG during the first quarter worth about $1,870,000. Renaissance Technologies LLC acquired a new stake in Nabriva Therapeutics AG during the fourth quarter worth about $103,000. Wellington Management Group LLP raised its stake in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the last quarter. Finally, Nationwide Fund Advisors acquired a new stake in Nabriva Therapeutics AG during the first quarter worth about $2,074,000. 56.65% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently weighed in on NBRV shares. HC Wainwright reaffirmed a “buy” rating on shares of Nabriva Therapeutics AG in a research note on Friday, May 12th. Cantor Fitzgerald set a $16.00 target price on shares of Nabriva Therapeutics AG and gave the company a “buy” rating in a research note on Thursday, May 11th. Zacks Investment Research raised shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Saturday, May 27th. ValuEngine raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Finally, Wedbush reissued an “outperform” rating and issued a $13.00 price objective on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $15.43.

About Nabriva Therapeutics AG

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

What are top analysts saying about Nabriva Therapeutics AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nabriva Therapeutics AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit